News

Francesco Di Marco Takes the Helm as Italfarmaco's CEO

Francesco Di Marco Takes the Helm as Italfarmaco's CEO

Francesco Di Marco Takes Over as Italfarmaco's CEO

Italfarmaco S.p.A. has made a significant announcement regarding its leadership. The company has appointed Dr. Francesco Di Marco as the Chief Executive Officer (CEO), with his official start date set for January 1, 2026. This decision is poised to steer Italfarmaco into its next phase of growth and innovation.

A Leader with Vast Experience

Dr. Di Marco comes with a wealth of experience, boasting over 25 years within the biopharmaceutical sector. He has previously held various executive positions that highlight his leadership capabilities. His journey at Italfarmaco commenced recently when he joined the Board of Directors on October 1, 2025, as part of a planned leadership transition.

Focus on Therapeutic Innovation

In his new role, Dr. Di Marco expressed his enthusiasm for Italfarmaco's commitment to advancing therapeutic innovation. "Italfarmaco has developed a comprehensive global presence with a diverse range of products, including treatments in haematology, oncology, cardiology, immunology, women's health, and rare diseases," he stated.

Commitment to Patients

One of the primary ambitions highlighted by Dr. Di Marco includes focusing on the treatment of diseases such as Duchenne muscular dystrophy through the company's innovative product givinostat (Duvyzat). He aims to enhance the impact Italfarmaco has on patients' lives by collaborating closely with their leadership team and other stakeholders.

Acknowledgement of Previous Leadership

The transition in leadership also carries gratitude towards outgoing CEO Carlos Barallobre. The Chairman of Italfarmaco Group, Francesco De Santis, expressed appreciation for Barallobre's decade-long contribution to the company. His efforts have undoubtedly positioned Italfarmaco for enduring success.

The Future Looks Bright

As Italfarmaco looks ahead, the company is focused on expanding its presence in key strategic markets. The leadership of Dr. Di Marco is expected to strengthen the company's established foundation and innovative spirit.

About Italfarmaco

Founded in 1938, Italfarmaco is a private global pharmaceutical company with a rich history of success in developing and commercializing numerous pharmaceutical products. Operating in over 90 countries, Italfarmaco excels at pharmaceutical research, product development, and offers comprehensive healthcare solutions. Its focus spans therapeutic areas including immuno-oncology, gynecology, neurology, and rare diseases.

Contacts

For Media Inquiries:

Anja Heuer / Adolfo Luna | +49 (0) 151 106 199 05 | italfarmaco@trophic.eu

For Other Inquiries:

Samantha Parker | Patient Advocacy and Communications Lead | RDEnquiries@italfarmacogroup.com

Frequently Asked Questions

Who is the new CEO of Italfarmaco?

The new CEO of Italfarmaco is Dr. Francesco Di Marco, effective January 1, 2026.

What experience does Francesco Di Marco bring?

He brings over 25 years of experience in the biopharmaceutical industry, having held various executive positions globally.

What are Italfarmaco's therapeutic priorities?

Italfarmaco focuses on treatments in haematology, oncology, cardiology, immunology, and rare diseases.

Who did Francesco Di Marco succeed as CEO?

He succeeded Carlos Barallobre, the outgoing CEO, who has been with the company for the past decade.

How long has Italfarmaco been in operation?

Italfarmaco was founded in 1938 and has a long history of pharmaceutical innovation and development.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 302

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 377

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 180

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 464

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 322

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 360

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 405

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Fibocom Unveils U6G Solutions Advancing Global 5G Tech

Updated Category News Views 80

Breaking Barriers with U6G-Capable Technology Sneaking into the industry's spotlight at MWC Doha 2026, Fibocom flaunts a robust lineup of next-gen 5G solutions. It's as if they're shuffling every card they’ve got to win over the broadband world. With breakthroughs like the FG390, FG370, and FG670 modules, alongside PCBA-level innovations, Fibocom is not just throwing...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 182

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 146

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading

Top 5 Most Recently Viewed Articles

Prodigy Processing Solutions Leads the Charge in Cannabis Extraction

Updated Category News Views 240

Prodigy Processing Solutions Steps into New York's Cannabis Scene Prodigy Processing Solutions is making strides in the cannabis industry by teaming up with ProXtracts Processing Inc., a leading cannabis oil producer, to initiate a pioneering hydrocarbon extraction lab. This collaboration highlights Prodigy's commitment to providing top-notch extraction technologies while...

Continue Reading
Key Details for Moderna Investors Regarding Class Action

Updated Category News Views 69

Important Information for Moderna, Inc. Investors The Gross Law Firm has an important update for shareholders of Moderna, Inc. (NASDAQ: MRNA). If you've purchased shares during the specific class period, you're encouraged to reach out to the firm about possibly serving as lead plaintiffs in an upcoming class action lawsuit. Class Period and Lead Plaintiff Information If...

Continue Reading
Vistagen Therapeutics Investors: Important Legal Update Ahead

Updated Category News Views 117

Vistagen Therapeutics' Legal Challenges: A Summary for Investors As a prominent player in the therapeutic landscape, Vistagen Therapeutics, Inc. (NASDAQ: VTGN) is currently navigating significant legal challenges that investors should be aware of. Legal representation is crucial for those who have invested in the company's stock, particularly following the announcement of...

Continue Reading
Nilfisk Holding A/S Unveils Key 2025 Financial Dates

Updated Category News Views 494

Nilfisk Holding A/S Financial Calendar for 2025 Nilfisk Holding A/S stands out as a prominent global player in the professional cleaning industry, consistently delivering high-quality products and services. As the new year approaches, the company has set forth significant dates for financial disclosures that are vital for investors and stakeholders alike. Upcoming Key...

Continue Reading
Exciting Return of Twang’s Signature Beer and Pickle Salts

Updated Category News Views 332

Exciting Announcement from Twang Twang, a beloved Latino-founded brand, has once again captured the hearts of flavor enthusiasts. Known for its innovative and enticing blends of flavored salts, Twang is thrilled to share the return of two highly anticipated products: Orange Beer Salt and Hot Pickle Flavored Salt. Fans of these tasty seasonings can look forward to their...

Continue Reading